安罗替尼三线治疗晚期肺癌的临床疗效及安全性分析

Clinical efficacy and safety evaluation of anlotinib in the third-line treatment of advanced lung cancer

目的观察安罗替尼三线治疗晚期肺癌的疗效和安全性。方法回顾性分析2018年1月至2019年9月,首都医科大学附属友谊医院肿瘤科接受12 mg安罗替尼三线治疗的晚期肺癌患者,治疗2个周期后观察癌胚抗原、血胆固醇和甘油三酯等指标以及影像学变化,评价客观缓解率、疾病控制率、无进展生存期,分析安罗替尼的临床疗效。结果纳入的37例肺癌患者中,完全缓解0例,部分缓解2例,疾病进展13例,疾病稳定22例,客观缓解率为5.41%,疾病控制率为64.86%。安罗替尼的安全性方面,发生率较高的不良反应为高血压1例,乏力3例,甘油三酯升高1例,出血1例,胃肠道不适4例,诱发癫痫1例。结论安罗替尼用于晚期肺癌三线治疗具有一定的效果,安全性可接受。

Objective To observe the efficacy and adverse reactions of anlotinib in the third-line treatment of advanced lung cancer.Methods From January 2018 to September 2019,the patients who received 12 mg of anlotinib hydrochloride in the third-line treatment of advanced cancer patients in the Friendship Hospital Affiliated to Capital Medical University were analyzed retrospectively.After two cycles of treatment,carcinoembryonic antigen,blood cholesterol,triglyceride and other indicators as well as imaging changes were observed.The objective remission rate(ORR),disease control rate(DCR)and progression-free survival period(PFS)were evaluated.The clinical efficacy of anlotinib was analyzed and the safety data were recorded.Results Among the 37 patients with lung cancer,there were 0 cases of complete remission(CR),2 cases of partial remission(PR),13 cases of disease progression(PD),22 cases of disease stability(SD),the ORR was 5.41%,and the DCR was 64.86%.In terms of safety,high incidence of adverse reactions were hypertension in 1 case,fatigue in3 cases,triglyceride increase in 1 case,hemorrhage in 1 case,gastrointestinal discomfort in 4 cases,and epilepsy induced in 1 case.Conclusion The third-line treatment of advanced lung cancer with anlotinib has certain effect and acceptable safety.